Vanadyl treatment normalizes submandibular salivary gland insulin-like immunoreactivity in streptozotocin-diabetic rats

Horm Metab Res. 1998 Mar;30(3):150-2. doi: 10.1055/s-2007-978855.

Abstract

Rat submandibular salivary glands (SSG) contain a compound displaying insulin-like immunoreactivity (ILI) and various biological activities of insulin. As SSG ILI levels were reported to be increased in streptozotocin (STZ)-induced diabetes but not normalized by a two-week insulin treatment, we decided to check whether another antidiabetic treatment, vanadyl sulphate (VOSO4), was able to regulate SSG ILI concentration. A short term (8 days) i.p. VOSO4 treatment (total dose = 1.3 mmol/kg) of rats made diabetic 8 days earlier by a single i.v. injection of STZ (60 mg/kg BW) was able to induce a long-term (4 weeks) correction of hyperglycemia while weight gain was re-established. In untreated diabetic animals (approximately -25%) and increased (approximately +175%) as compared to normal rats. Both parameters were normalized in VOSO4-treated diabetic rats.

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / metabolism*
  • Hypoglycemic Agents / pharmacology*
  • Insulin / metabolism*
  • Male
  • Rats
  • Rats, Wistar
  • Submandibular Gland / anatomy & histology
  • Submandibular Gland / drug effects*
  • Submandibular Gland / metabolism*
  • Vanadium Compounds / therapeutic use*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Vanadium Compounds
  • vanadyl sulfate